KCKim Cocks

Kim Cocks

*This is an algorithmically generated author record based on publicly available information.

Kim Cocks has a total of 355 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Derivation of Score Interpretation Thresholds in Clinical Outcome Assessments Measuring Cognitive Impairment Associated with Schizophrenia

    by Gillian Worthy, Kim Cocks, Ben Pascoe, Matt Reaney, Hans Klein, Piper Fromy, Corey Fowler, Alexandra Lauer, Stephanie Sommer, Christina Daskalopoulou, et al.

    BackgroundCognitive impairment is a major factor impacting the functioning and quality of life of individuals with schizophrenia. Several clinical outcome assessment (COA) measures have been developed to measure various aspects of cognition. This study aimed to identify thresholds for interpreting changes that would be meaningful to patients.MethodsThe study utilised COA data from a multinational program of randomised controlled trials evaluating iclepertin for the treatment of cognitive impairment associated with schizophrenia (CIAS). Endpoints included the MATRICS Consensus Cognitive Battery (MCCB), Schizophrenia Cognition Rating Scale (SCoRS), Virtual Reality Functional Capacity Assessment Tool (VRFCAT) and Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS). Analysis utilised anchor-based methods supported by distribution-based methods to derive interpretation thresholds. Triangulation resulted in a single value or small range of values for between-group difference and meaningful within-patient change (MWPC) thresholds.ResultsMWPC thresholds for improvement were increases of 4 to 7 points for MCCB overall composite T-score and 10 points for VRFCAT overall T-score and decreases of 5 to 7 points for SCoRS interviewer total score and 0.4 to 0.6 points for PRECIS total score. MCCB and VRFCAT thresholds were estimated using distribution-based methods due to insufficient correlation between anchors and the target scores.ConclusionThe proposed score interpretation thresholds may be valuable for assessing improvement in CIAS in future clinical research. Anchor-based analyses may be limited in this patient population as patient, caregiver and clinician-based global ratings of severity tend to have low correlations with multi-item COA scores, particularly with performance-based measures.

  • Defining thresholds for meaningful interpretation of patient-reported outcome scores

    by Kim Cocks, Johannes M. Giesinger

    Purpose of review: There are many different patient-reported outcome measures to assess how patients feel or function but they vary in how they collect responses and score results. Therefore, it can be hard to know what a change in score means for a patient or whether treatments compared in a trial result in different patient experiences. Methods exist to estimate thresholds to aid interpretation, but no single method is considered the best. This review considers recent advances in efforts to improve these methods. Recent findings: New research has been published on the choice of appropriate anchors and the methods to establish thresholds based on them. There has been increased focus on the derivation of thresholds used to compare scores between groups of patients versus those used to interpret an individual’s change in scores over time. Studies are also highlighting how baseline severity and other factors affect how we estimate thresholds. Summary: Consensus on the optimal methods for the derivation of score interpretation thresholds is still required, although the field continues to grow in understanding biases and impacts of treatment and population factors on estimation.


  • Open Access

    Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

    by Horst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, Martin Reck, Hiroaki Akamatsu, Suresh S. Ramalingam, Hossein Borghaei, Melissa Johnson, Franziska Dirnberger, Kim Cocks, et al.

    Introduction Tarlatamab demonstrated a durable response and promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) in the phase 2, open-label DeLLphi-301 trial. Patient-reported outcomes (PROs) were evaluated to assess the benefit-risk profile of tarlatamab. Methods Patients received tarlatamab intravenously every 2 weeks at a dose of 10 mg (regulatory approved dose) or 100-mg until progression or loss of benefit. PROs, including European Organization for Research and Treatment of Cancer 30-item Quality of Life Questionnaire (EORTC-QLQ-C30) and 13-item lung cancer module (LC13), Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and the GP5 question of the Functional Assessment of Cancer Therapy – General Form (FACT-GP5), were collected at Cycle 1 (days 1, 8, 22), Cycle 2 (days 1, 15) and every 6 weeks from Cycle 3 onwards. PROs were summarized descriptively alongside the amount and reason for missing data and analyzed using a mixed model for repeated measures. In addition, median time to deterioration (TTD) for symptom and functional scales was analyzed. Results A total of 100 patients were PRO-evaluable at the selected target dose (10 mg). EORTC-QLQ-C30 and LC13 completion rates (proportion of PRO assessments expected to be completed) were high (> 80%) throughout the study. Least square mean changes from baseline showed a trend towards improvement for the QLQ-C30 subscale of global health status and stabilization for physical functioning. Patients experienced reduced symptom burden for dyspnea which was more pronounced for patients at later cycles (≥ 10 points), and stabilization for chest pain and cough. Median TTD exceeded 6 months for cough and dyspnea and was not estimable for chest pain. Overall, tarlatamab was well tolerated with the majority of patients reporting no bother or a little bit of bother from side effects post baseline. Patient-reported adverse events were generally of mild to moderate severity occurring rarely or occasionally. Conclusion Alongside previously reported antitumor activity, tarlatamab demonstrated a positive benefit–risk profile in previously treated SCLC with favorable PROs across a range of functional outcomes and symptoms, while showing manageable and sustained tolerability. ClinicalTrials.gov Number NCT05060016.


  • Open Access

    Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations

    by Kim Cocks, Bellinda L. King-Kallimanis, Joel Sims, Gill Worthy, Julia Stein, Lara Ayala–Nunes, Monika Achra, Zhanglin Lin Cui, Nalin Payakachat

    Background: Time to deterioration (TTD) endpoints are often utilized in the analysis of patient-reported outcome (PRO) data in oncology clinical trials but different endpoint definitions and analysis frameworks exist that can impact result interpretation. This review examined the analysis, reporting and heterogeneity of TTD endpoints in the literature, the impact of analysis methods on results, and provides recommendations for future trials. Methods: A targeted literature review of articles published between 2017 and 2022 was performed to collate TTD endpoints reported in oncology randomized controlled trials (RCTs). Details of endpoints and results were extracted including; deterioration definition, PRO assessment schedule, methods for handling intercurrent events, statistical analysis methods, main trial results (overall survival and/or progression-free survival) and TTD endpoint results. Results: Seventy RCTs were included covering 849 individual TTD endpoints. There were 17 primary cancer types, with lung (26%), breast (11%), and prostate (7%) cancers the most common. Most trials (71%) were for people with advanced cancer. Full definitions of TTD endpoints were often missing. There were no clear trends for a specific TTD definition within cancer types or stages. However, statistical analysis methods were consistent among trials. Conclusion: The TTD definition can vary and is ultimately driven by the research question. Points to consider for successfully implementing PRO TTD endpoints in oncology include consideration of the trial setting (e.g., early vs. advanced cancer), expected treatment effect (e.g., improvement vs. worsening), likely adverse event profile (including early vs. delayed) and PRO data collection frequency in order to improve utility of these endpoints.


  • Open Access

    Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

    by K. Forde, K. Cocks, J. R. Wells, I. McMillan, C. Kyriakou, EORTC Quality of Life Group

    The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement.The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues.An electronic database search was conducted (1996-June 2020) to identify clinical studies/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications/conference abstracts and checked by a second rater.The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional (n = 21, 32%) and observational (n = 44, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients (n = 15, 68%) and assessed a range of combinations therapies.QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary (n = 12, 55%) or exploratory (n = 7, 32%) trial endpoints, particularly DS (n = 16, 72%) and SE (n = 16, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (>0.7), test-reset reliability (intraclass correlation coefficient > =0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects.The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment.


  • How strong should my anchor be for estimating group and individual level meaningful change? A simulation study assessing anchor correlation strength and the impact of sample size, distribution of change scores and methodology on establishing a true meaningful change threshold

    by Philip Griffiths, Joel Sims, Abi Williams, Nicola Williamson, David Cella, Elaine Brohan, Kim Cocks

    Purpose Treatment benefit as assessed using clinical outcome assessments (COAs), is a key endpoint in many clinical trials at both the individual and group level. Anchor-based methods can aid interpretation of COA change scores beyond statistical significance, and help derive a meaningful change threshold (MCT). However, evidence-based guidance on the selection of appropriately related anchors is lacking. Methods A simulation was conducted which varied sample size, change score variability and anchor correlation strength to assess the impact of these variables on recovering the simulated MCT for interpreting individual and group-level results. To assess MCTs derived at the individual-level (i.e. responder definitions; RDs), Receiver Operating Characteristic (ROC) curves and Predictive Modelling (PM) analyses were conducted. To assess MCTs for interpreting change at the group-level, the mean change method was conducted. Results Sample sizes, change score variability and magnitude of anchor correlation affected accuracy of the estimated MCT. For individual-level RDs, ROC curves were less accurate than PM methods at recovering the true MCT. For both methods, smaller samples led to higher variability in the returned MCT, but higher variability still using ROC. Anchors with weaker correlations with COA change scores had increased variability in the estimated MCT. An anchor correlation of around 0.50–0.60 identified a true MCT cut-point under certain conditions using ROC. However, anchor correlations as low as 0.30 were appropriate when using PM under certain conditions. For interpreting group-level results, the MCT derived using the mean change method was consistently underestimated regardless of the anchor correlation. Conclusion Sample size and change score variability influence the necessary anchor correlation strength when recovering individual-level RDs. Often, this needs to be higher than the commonly accepted threshold of 0.30. Stronger correlations than 0.30 are required when using the mean change method. Results can assist researchers selecting and assessing the quality of anchors.


  • Top Cited Papers
    Open Access

    Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer

    by Kim Cocks, Jane R. Wells, Colin Johnson, Heike Schmidt, Michael Koller, Simone Oerlemans, Galina Velikova, Monica Pinto, Krzysztof A. Tomaszewski, Neil K. Aaronson, et al.


  • How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

    by Kim Cocks, Jacqueline Buchanan

    Purpose The recommended method for establishing a meaningful threshold for individual changes in patient-reported outcome (PRO) scores over time uses an anchor-based method. The patients assess their perceived level of change and this is used to define a threshold on the PRO score which may be considered meaningful to the patient. In practice, such an anchor may not be available. In the absence of alternative information often the meaningful change threshold for assessing between-group differences, the minimally important difference, is used to define meaningful change at the individual level too. This paper will highlight the issues with this, especially where the underlying measurement scale is not continuous. Methods Using the EORTC QLQ-C30 as an example, plausible score increments (“state changes”) are calculated for each subscale highlighting why commonly used thresholds may be misleading, including leading to sensitivity analyses that are inadvertently testing the same underlying threshold. Results The minimal possible individual score change varies across subscales; 6.7 for Physical Functioning, 8.3 for Global Health Scale and Emotional Functioning, 11.1 for fatigue, 16.7 for role functioning, cognitive functioning, social functioning, nausea and vomiting, pain and 33.3 for single items. Conclusions The determination of meaningful change for an individual patient requires input from the patients but being mindful of the underlying scale ensures that these thresholds are also guided by what is a plausible change for patients to achieve on the scale.


  • Open Access

    Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients

    by Pip Griffiths, John Devin Peipert, Andrea Leith, Alex Rider, Lucy Morgan, David Cella, Kim Cocks

    Purpose: With higher efficacy of cancer therapies, the numbers and types of side effects experienced by patients have also increased, evidencing a need for brief assessments of side effect bother. The Functional Assessment of Cancer Therapy-General (FACT-G) includes the item “I am bothered by side effects of treatment” (GP5). This study aimed to confirm GP5’s validity in a large, diverse, real-world patient sample. Methods: Real-world data were drawn from 10 Adelphi Disease Specific Programmes (DSP™) conducted between 2015 and 2019 in France, Germany, Italy, Spain, the UK and the USA, covering 10 cancer sites. We examined correlations between GP5 responses and varied measures of patient-reported global health and the number of side effects experienced. We explored whether more advanced patients and those with worse Eastern Cooperative Oncology Group Performance Status Rating (ECOG PSR) reported greater side effect bother. Finally, we conducted differential item functioning (DIF) assessment using the Mantel–Haenszel approach. Results: The sample included 6755 advanced cancer patients. GP5 responses were distributed similarly across most cancer sites. A moderate, negative correlation (rpolyserial = − 0.43) between GP5 responses and global health evidenced convergent validity. Known groups validity was evidenced by dichotomised distributions of GP5, showing expected results between cancer stage 2 vs. 3 and 4 and with ECOG PSR (p < 0.001). Little evidence of DIF was found. Conclusion: GP5 exhibited evidence of validity across cancer sites and countries and appeared to measure the same construct across these countries. GP5 has significant promise as a summary indicator of side effect bother.